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http://dx.doi.org/10.1016/j.ccr.2013.08.005SUMMARYThe epithelial-mesenchymal transition program becomes activated during malignant progression and can
enrich for cancer stem cells (CSCs). We report that inhibition of protein kinase C a (PKCa) specifically targets
CSCs but has little effect on non-CSCs. The formation of CSCs from non-stem cells involves a shift from
EGFR to PDGFR signaling and results in the PKCa-dependent activation of FRA1. We identified an AP-1
molecular switch in which c-FOS and FRA1 are preferentially utilized in non-CSCs and CSCs, respectively.
PKCa and FRA1 expression is associated with the aggressive triple-negative breast cancers, and the deple-
tion of FRA1 results in a mesenchymal-epithelial transition. Hence, identifying molecular features that shift
between cell states can be exploited to target signaling components critical to CSCs.INTRODUCTION
Cancer stem cells (CSCs), which are defined by their tumor-initi-
ating properties, have been identified within breast, colon, head
and neck, lung, and prostate carcinomas (Ailles and Weissman,
2007). These cells appear to be responsible for driving tumor
growth, recurrence, and metastasis (Al-Hajj et al., 2003; Dalerba
et al., 2007). In experimental models of cancer development,
treatment of bulk cancer cell populations within tumors or cancer
cell lines propagated in culture with chemotherapy or radio-
therapy has been shown to select for the outgrowth of
therapy-resistant subpopulations of cancer cells that are more
tumorigenic, invasive, and stem like (Creighton et al., 2009;
Gupta et al., 2009). Hence, cancer therapies may be renderedSignificance
Conventional cancer therapeutics tend to preferentially elimin
more resistant CSCs that can subsequently generate clinical r
within tumors. The identification of key regulatory mechanism
for CSC-targeted therapy. We find that the PKCa signaling ne
erentially susceptible to specific pharmacologic agents. In ad
downstream of PKCa that drives CSC function. The inhibition
lighting the potential therapeutic value of targeting these prot
Caineffective because the bulk of cancer cells within a tumor may
be eliminated while leaving behind CSC-enriched cells that pro-
ceed to regenerate tumors. These tumors are often more malig-
nant than was observed prior to treatment, underscoring the
need for a detailed understanding of the molecular differences
between CSCs and non-CSCs to discover and exploit cell-
state-specific features that may render CSCs susceptible to
selective therapeutic intervention.
Numerous studies have used existing cancer cell lines to iden-
tify compounds that target cells bearing specific gene mutations
or exhibiting a more malignant phenotype; these studies did not,
however, address the specific effects of certain treatments on
CSCs because the representation of CSCs within these cell
lines was poorly defined. In the case of breast cancer, severalate the non-CSCs within a tumor, leaving behind residues of
elapses, indicating the need to specifically target the CSCs
s that distinguish CSCs from non-CSCs is therefore critical
twork is activated specifically in CSCs, rendering them pref-
dition, we uncovered FRA1 to be a key transcription factor
of either PKCa or FRA1 can abolish tumor initiation, high-
eins in epithelial cancers such as breast cancer.
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Hoechst dye efflux, and the retention of the PKH26 lipophilic
dye, have been shown to enrich for CSCs in various cell lines
(Al-Hajj et al., 2003; Ginestier et al., 2007; Pece et al., 2010).
However, regardless of the enrichment procedure, these initially
purified cells with CSC properties often differentiate rapidly into
cells exhibiting a non-CSC profile, making it difficult to identify
cell-state-specific inhibitors in vitro.
CSCs are generated in some and perhaps all carcinomas as
one of the products of an epithelial-mesenchymal transition
(EMT), indicating that these cells possess a more mesenchymal
phenotype that is associated with highly aggressive traits (Nieto,
2011; Thiery et al., 2009). We undertook to develop a method by
which we could clearly distinguish chemical inhibitors that target
breast CSCs from those that affect non-CSCs. Within normal
mammary epithelial cells (MECs), the forced expression of
EMT-inducing transcription factors (EMT-TFs) endows cells
with mesenchymal traits accompanied by the loss of epithelial
markers. These cells were shown to possess enhanced stem
cell activity in vitro and in vivo (Mani et al., 2008; Morel et al.,
2008). Likewise, in populations of weakly or non-tumorigenic
breast cancer cells, passage through the EMT program dramat-
ically increases CSC frequency along with the acquisition of
mesenchymal properties that include a distinctive CD44hi/
CD24lo cell-surface marker profile, mammosphere-forming abil-
ity, heightened resistance to chemotherapeutics, and increased
tumor-initiating ability (Nieto, 2011; Thiery et al., 2009).
In the present work, we took a directed approach to discover
key regulatory genes unique to the mesenchymal state whose
expression is elevated in CSCs.
RESULTS
Identification of Kinases Expressed Differentially in
EMT-Induced Cells
To understand the molecular changes associated with epithelial
cells that have passed through an EMT, we transduced genes
encoding the Twist, Snail, and Slug EMT-TFs into HMLE human
MECs that had previously been immortalized through the intro-
duction of the hTERT and SV40 early-region genes (Mani et al.,
2008). As anticipated, the resulting cells (HMLE-Twist, HMLE-
Snail, and HMLE-Slug) displayed a set of mesenchymal markers
and were judged by these criteria to have undergone an EMT
(Figure 1A and Figure S1A available online). These cells were
predominantly CD44hi/CD24lo (data not shown) and formed
mammospheres more efficiently than did the parental epithelial
cells (Figure 1B), indicating they were enriched for stem cell
activity.Figure 1. Global Gene Expression Analyses Reveal Differentially Regu
(A) Representative phase contrast images of the indicated cell lines (left) and qua
relative to HMLE-vector cells (right). Numbers denote fold change. Scale bar: 40
(B) Mammosphere-forming ability of HMLE cells transduced with Twist, Snail, or
(C) Heatmap of the top differentially regulated genes among HMLE-Twist, HMLE
(D) Phase contrast images of NAMEC and HMLE cells are shown. Scale bar: 40
(E) Quantitative PCR for gene expression of EMT markers in NAMEC8 and HMLE
(F) Western blots of EMT-associated proteins in NAMECs and HMLE cells are sh
(G) Flow cytometry analysis for the expression of CD44 and CD24 surface antige
(H) Mammosphere-forming ability of NAMECs and HMLE cells is depicted.
*p < 0.05. Data are presented as mean ± SEM. See also Table S1 and Figure S1
CaUsing microarray gene expression analyses (GSE43495),
we searched for kinase-encoding genes that exhibited the
greatest differences in expression in the EMT-TF-induced
mesenchymal cells relative to the parental HMLE cells. A
group of kinase-encoding genes was overexpressed at least
2-fold in HMLE-Twist, HMLE-Snail, and HMLE-Slug cells
relative to the HMLE population (Figure 1C; Table S1). Several
of these genes, including CLK1, EPHA2, NME7, PRKCA
(hereafter referred as PKCa), SGK1, SPHK1, and CDK6, have
been reported to promote cancer cell invasion and motility
but were not previously implicated either as components of
the EMT transcription program or in the maintenance of
mesenchymal and CSC states. We validated the expression
of the top selected kinase mRNAs by quantitative PCR
(Figure S1B).
The changes in the expression patterns of these kinases
during the EMT suggested an opportunity for selective thera-
peutic intervention using kinase inhibitors. We wished to
develop an assay that could be used to determine whether
any of the upregulated kinases could be pharmacologically
targeted to preferentially kill the mesenchymal cells. Because
the mesenchymal cells analyzed above carried constitutively
expressed EMT-TFs and were therefore locked in the mesen-
chymal state, we reasoned their response to chemical inhibi-
tors might not be representative of mesenchymal cells that
arise in vivo through the physiological and presumably revers-
ible upregulation of endogenous EMT-TFs, limiting the utility
of the EMT-TF vector-transduced cells in chemical inhibitor
screens.
Therefore, we derived populations of HMLE cells that had
spontaneously undergone an EMT and stably resided there-
after in a mesenchymal state (Figure 1D). Hence, their
phenotypic state was governed by endogenously expressed
EMT-TFs. We derived 11 such lines, termed naturally arising
mesenchymal cells (NAMECs), from bulk cultures of HMLE
cells. We found that NAMECs expressed elevated levels of
endogenous EMT-TFs (Twist, Snail, Slug, and Zeb1) and
associated markers (vimentin, N-cadherin, and fibronectin) as
well as loss of the key epithelial adherens junction protein,
E-cadherin (encoded by CDH1) (Figures 1E, 1F, S1A, and
S1C). Similar to EMT-TF-induced cells and the resident
mammary epithelial stem cells that are naturally present
within HMLE populations, NAMECs were also predominately
CD44hi/CD24lo (Figure 1G). They exhibited an 11.3-fold higher
mammosphere-forming ability relative to HMLE cells (Fig-
ure 1H). Thus, NAMECs exhibited characteristics of cells that
have passed through an EMT and differed greatly from parental
HMLE cells.lated Kinases Whose mRNA Expression Are Altered following EMT
ntitative PCR for gene expression of EMT markers in these cell lines are shown
mm.
Slug is shown.
-Snail, HMLE-Slug, and control cells is shown (fold change > 1.2).
mm.
cells is shown.
own. Samples were loaded and analyzed on the same blot.
ns on NAMECs and HMLE cells.
.
ncer Cell 24, 347–364, September 9, 2013 ª2013 Elsevier Inc. 349
PKC 20-28 Ro-32-0432Bisindol I
Control
Ro-31-8220
JAK InhCAY10621 SKI2
Fluphenazine R24571J8 W7
Paclitaxel
PD0332991 PKCηTG003
Doxorubicin
GSK650394
Staurosporine
A B
PKC 20-28 Ro-31-8220 Bisindolylmalmide
Co
nt
ro
l
Tr
ea
te
d
Mes (Tom)
Ep
i(
G
FP
)
C D
G
Inhibitor added daily
Vehicle
(DMSO)
Kinase
Inhibitor
6 days
NAMEC 
(Mesenchymal)
75 000 cells/ well
HMLE 
(Epithelial)
15 000 cells/ well
Tomato
G
FP
HMLE
NAMEC
G
FP
Tomato
100 μm
Ro-31-8220Vehicle (DMSO) Paclitaxel Staurosporine
H
M
LE
N
A
M
EC
Annexin V - APC
22.4%
89.4% 22.3%
89.1%
29.7%
93.1%Apoptoc cells
Apoptoc cells
FE
0
0.5
1
1.5
N
A
M
EC
-T
om
H
M
LE
-G
FP
PKCα sh1 PKCα sh2
Luc sh Vector
Re
la
v
e 
ge
ne
 e
xp
re
ss
io
n
*
* *
*
HMLE-GFP
Re
la
v
e 
ce
ll 
nu
m
be
r (
O
.D
. 4
50
 n
m
)
Day
0
2
4
6
8
1 2 4 6
PKCα sh1
PKCα sh2
Luc sh
Vector
NAMEC-Tom
Re
la
v
e 
ce
ll 
nu
m
be
r (
O
.D
. 4
50
 n
m
)
0
1
2
3
4
1 2 4 6
PKCα sh1
PKCα sh2
Luc sh
Vector *
*
Day
H I
Re
la
v
e 
ge
ne
 e
xp
re
ss
io
n *
0
5
10
15
CD24
CD
44
100 μm
12.07 x 9.62 x
132.4 x7.52 x
6.84 x
0
2
4
6
8
10
12
14
Co
nt
ro
l
Tw
is
t
Sn
ai
l
Sl
ug
N
A
M
EC
3
N
A
M
EC
5
N
A
M
EC
8
PK
C 
ac
v
ity
 (r
el
a
ve
 t
o 
co
nt
ro
l)
CD
44
hi
/C
D
24
lo
CD
44
lo
/C
D
24
hi
U
nf
ra
c
on
at
ed
(legend on next page)
Cancer Cell
PKCa Signaling Network in Breast Cancer Stem Cells
350 Cancer Cell 24, 347–364, September 9, 2013 ª2013 Elsevier Inc.
Cancer Cell
PKCa Signaling Network in Breast Cancer Stem CellsDepletion of Stem-like Cells by Select Kinase Inhibitors
To identify kinase inhibitors that selectively targeted mesen-
chymal-like cells bearing stem cell properties, we established a
screen that measured the ability of candidate inhibitors to prefer-
entially deplete mesenchymal NAMECs but not HMLE cells. We
labeled one of the NAMEC lines (NAMEC8) with the tdTomato
red fluorescent protein (NAMEC-Tom) and the HMLE cells with
green fluorescent protein (HMLE-GFP). We then attempted to
reconstitute certain stem cell and non-stem-cell interactions
that might operate in vivo by mixing the two cell populations in
culture in a 5:1 ratio (Figures 2A and S2A). We then challenged
these cultures with a panel of kinase inhibitors. We initially tar-
geted several protein kinases that were elevated in HMLE-Twist,
HMLE-Snail, and HMLE-Slug cells and NAMECs relative to
HMLE using of a panel of 15 commercially available kinase inhib-
itors (Figures 1C, S1B, and S2B). Figure 2B illustrates their
effects on the proportion of surviving NAMEC-Tom and HMLE-
GFP cells at the end of a 6-day treatment period. The numbers
of viable cells were quantified with flow cytometry to determine
the fraction of NAMEC-Tom or HMLE-GFP cells in inhibitor-
treated populations relative to vehicle-treated controls.
The four inhibitors targeting PKCa (PKC 20-28, Ro-31-8220,
Ro-32-0432, and bisindolylmaleimide I) showed a 6.8- to 12.1-
fold lower lethal concentration (LC50, 50%) against NAMEC-
Tom cells relative to HMLE-GFP cells (Figures 2C and 2D). These
findings were validated in three other NAMEC cell lines (Figures
S2C and S2D). Because PKCa was also elevated in CD44hi/
CD24lo HMLE cells (Figure 2E), we tested whether these stem-
like cells were sensitive to the inhibitors. Indeed, treatment of
bulk HMLE cells with two different PKCa inhibitors reduced the
CD44hi/CD24lo cell compartment, whereas the CD44lo/CD24hi
population remained unaffected (Figure S2E).
Although total and phosphorylated PKCawere overexpressed
in a variety of derived mesenchymal cells (Figure S2F), the
phosphorylation status of PKCa is constitutive and not a useful
indicator of its activity (Newton, 2001). Furthermore, active site
inhibitors, such as bisindolylmaleimide, could paradoxically sta-
bilize phosphorylated PKC (Cameron et al., 2009; Gould et al.,
2011). Accordingly, we validated PKC enzymatic activity in these
cells and found that the derived mesenchymal cells possessed
on average 8.5-fold higher levels of total PKC activity relative
to HMLE cells (Figure 2F).Figure 2. PKCa Inhibition Selectively Targets Cells that Have Undergo
(A) This is the approach for testing kinase inhibitors to identify stem-cell-specific c
24 hr prior to daily inhibitor treatment. Viable cells were analyzed after 6 days by fl
(B) The proportion of surviving NAMEC-Tom and HMLE-GFP cells is shown as v
(C) Viable cell populations were analyzed by flow cytometry that segregated and co
Cell numbers of each population were normalized to corresponding NAMEC-Tom
(D) Dose-response curves of NAMEC-Tom and HMLE-GFP cells treated with P
between NAMEC-Tom and HMLE-GFP cells at each inhibitor is indicated. Curves
variable slope model.
(E) Quantitative PCR for PKCa mRNA level in CD44hi/CD24lo, CD44lo/CD24hi, an
(F) Levels of total PKC kinase activity in EMT-TF-induced HMLE and NAMEC ce
(G) Measurement of apoptosis by Annexin V-APC in mixed NAMEC-Tom and HM
(H) Quantitative PCR for validation of PKCa RNAi knockdown in NAMEC-Tom an
denotes a significant difference from the Luc sh control.
(I) Effects of PKCaRNAi on the growth kinetics of NAMEC-Tom and HMLE-GFP ce
difference from the Luc sh control.
*p < 0.05. Data are presented as mean ± SEM. See also Figure S2.
CaThe inhibitors targeting PKCh, CLK1, CDK6, and JAK1 also
appeared to depleteNAMEC-Tomcells preferentially (Figure 2B).
However, these agents were not included in subsequent
studies because only a single inhibitor was available against
each of these kinases, preventing us from controlling for
possible off-target effects. In stark contrast to the effect of the
pathway-specific inhibitors, three non-pathway-specific com-
pounds, staurosporine, doxorubicin, and paclitaxel, preferen-
tially depleted HMLE-GFP cells instead (Figures 2B and 2D).
This supported previous observations that non-cell-state-
specific inhibitors can enhance the representation of more
aggressive cancer stem-like cells within heterogeneous cell
populations following treatment (Creighton et al., 2009; Gupta
et al., 2009).
To determine how PKCa inhibitors affected these more
susceptible cell populations, we tested whether they induced
apoptosis. The mixed cell populations were treated with Ro-
31-8220 for 3 days; 89.4% of NAMEC-Tom cells underwent
apoptosis in comparison to 22.4% of the HMLE-GFP cells
(Figure 2G). Conversely, paclitaxel and staurosporine resulted
in HMLE-GFP cell apoptosis, leaving NAMEC-Tom cells less
affected.
Because it remained possible that the four PKCa inhibitors
used in our analyses acted in an off-target manner, we depleted
PKCa with shRNA (Figure 2H). Mixed NAMEC-Tom and HMLE-
GFP cultures were infected with lentiviral shRNAs targeting
PKCa and then seeded separately, after sorting for either Tom+
or GFP+ expression. Consistent with the use of chemical inhibi-
tors, depletion of PKCa resulted in the substantial loss of
NAMECs, whereas HMLE cells were less affected (Figure 2I).
These observations confirmed the greater dependence on
PKCa-regulated signaling networks in cells that have passed
through an EMT program.
Conservation of Cell-State-Specific Features upon
Oncogenic Transformation
To test whether neoplastic cells that have passed through an
EMT program acquire a greater potential to generate CSCs,
we ectopically expressed comparable levels of H-RASG12V in
NAMECs and HMLE cells (Figure 3A). As few as 500 of the result-
ing NAMEC-RAS cells, when implanted into NOD-SCID mice,
were sufficient for tumor initiation in 6 out of 10 hosts, whereasne an EMT and Are Enriched for Stem Cell Properties
ompounds. NAMEC-Tom and HMLE-GFP cells were comixed and seeded for
ow cytometry to determine the proportion of NAMEC-Tom or HMLE-GFP cells.
isualized by fluorescence microscopy after 6 days of inhibitor treatment.
unted NAMEC-Tom andHMLE-GFP cells after treatment with PKCa inhibitors.
or HMLE-GFP cells of DMSO-treated controls.
KCa inhibitors, paclitaxel, or staurosporine are shown. The difference in LC50
for each cell type were generated using non-linear-regression curve fit with the
d unfractionated cell compartments of HMLE cells is shown.
lls relative to HMLE control cells are shown.
LE-GFP cells treated with Ro-31-8220 for 3 days is depicted.
d HMLE-GFP cells 3 days after puromycin selection is shown. The asterisk (*)
lls as measured byWST assay are shown. The asterisk (*) denotes a significant
ncer Cell 24, 347–364, September 9, 2013 ª2013 Elsevier Inc. 351
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to form tumors (Figure 3A). Based on a limiting dilution assay, the
frequency of CSCs was calculated to be approximately 1/2,314
for NAMEC-RAS and 1/463,783 for HMLE-RAS cells. Thus,
transformation of preneoplastic stem cells expressing mesen-
chymal traits gave rise to CSCs far more efficiently than bulk
epithelial cells.
To investigate whether PKCa inhibition would also preferen-
tially affect CSC-enriched NAMEC-RAS cells, we first deter-
mined whether PKCa mRNA levels remained differentially
regulated between NAMEC-RAS and HMLE-RAS cell popula-
tions. We found that the mRNA levels of PKCa and other
kinase-encoding genes that were examined previously remained
higher in NAMEC-RAS cells compared to the HMLE-RAS cells;
this echoed the behavior of EMT-TF-inducedmesenchymal cells
that had been transduced with the RASG12V vector (Figure 3B).
We then mixed NAMEC-RAS cells labeled with tdTomato
(NAMEC-Tom-RAS) and HMLE-RAS cells labeled with GFP
(HMLE-GFP-RAS), retested the effects of kinase inhibition, and
found that NAMEC-Tom-RAS cells were more sensitive to
PKCa inhibition relative to HMLE-GFP-RAS cells (Figure 3C). In
contrast, NAMEC-Tom-RAS cells were more resistant to pacli-
taxel and staurosporine than were HMLE-GFP-RAS cells (Fig-
ure 3C). When these various transformed cell populations were
implanted into NOD-SCID mice, NAMEC-RAS-derived tumors
continued to express PKCa, but HMLE-RAS tumors did not
(Figure 3D).
To assess the therapeutic utility of PKCa inhibitors, NAMEC-
RAS cells were implanted in NOD-SCID mice and treated for
30 days with a daily intraperitoneal dose of either a PKCa inhib-
itor (Ro-31-8220) or a DMSO solvent control; additional control
animals were left untreated. These dosages were well tolerated
in mice and had no adverse effects after 30 days of treatment
followed by 8 weeks of observation. Significant tumor burdens
were observed after 15 weeks in all control-treated mice,
whereas only four of eight mice treated with PKCa inhibitor
formed tumors (Figure 3E). Hence, PKCa inhibition reduced
tumor-initiating frequency and tumor growth of the CSC-
enriched populations in vivo. We also examined whether PKCa
inhibition would have any effect on the growth of already estab-
lished tumors. Xenografted NAMEC-RAS tumors were allowed
to reach approximately 2 mm in diameter (assessed by palpa-
tion) 4 weeks after implantation and then exposed to treatments.Figure 3. Cell-State-Specific Kinase Expression Is Conserved upon On
(A) Assessment of the tumorigenicity of NAMEC-RAS or HMLE-RAS cells injected
by tumor mass, is shown. Numbers indicate the frequency of tumor formation. W
(B) Quantitative PCR for gene expression of selected kinases in HMLE-Twist-RAS
to HMLE-RAS cells.
(C) Dose-response curves of NAMEC-Tom-RAS and HMLE-GFP-RAS cells trea
sensitivity to treatment at LC50 is indicated.
(D) Immunohistochemistry detection of total PKCa and p-PKCaT497 in sections
NAMEC-RAS tumors were 15 weeks after inoculation of 2.5 3 104 cells, and HM
(E) Assessment of the tumorigenicity of subcutaneously xenografted NAMEC-RA
indicated agents, as determined by tumor mass, is shown. Treatments began on t
implantation.
(F) Assessment of the tumorigenicity of established NAMEC-RAS tumors followi
were subcutaneously xenografted in mice and allowed to reach approximately
intraperitoneal administration of the indicated agents for 30 days. Tumors were c
*p < 0.005. Data are presented as mean ± SEM.
CaTumors from control-treated mice reached 1.03 g 6 weeks
later, whereas those from PKCa-inhibitor-treated mice only
weighed 0.25 g (Figure 3F). These results demonstrated the
therapeutic effects of PKCa inhibition on the continued growth
of already-established tumors.
A Switch from EGFR to PDGFR Signaling Is Induced
upon EMT
The greater reliance of CSCs onPKCa led us to question whether
cells that have passed through an EMT respond to mitogenic
and trophic signals differently from those that have not. We
attempted to trace the sources of the upstream signals that
might be responsible for activating PKCa and postulated that
certain receptor tyrosine kinases induced by the EMT program
might be involved. We speculated that the EGF receptor
(EGFR) might activate PKCa in cells that had undergone an
EMT because EGFR overexpression and amplification are posi-
tively associated with breast cancer progression (Carey et al.,
2010). However, in mesenchymal cell populations, the expres-
sion of endogenous total and phosphorylated EGFRY1068 was
reduced relative to HMLE cells (Figure 4A). Treatment of com-
ixed NAMEC-RAS-Tom and HMLE-RAS-GFP cells with either
of two EGFR inhibitors preferentially selected against HMLE-
RAS-GFP cells (Figure 4B). Hence, the more epithelial, non-
CSC-enriched populations depended more strongly upon
sustained EGFR signaling than did the mesenchymal CSC-
enriched cell populations.
We used proteome analysis to identify potential RTKs associ-
atedwith an EMT and responsible for the activation of PKCa. The
most differentially expressed RTK, exhibiting a 13-fold increase
in representative peptides in HMLE-Twist cells relative to
HMLE cells, was PDGFRb (encoded by PDGFRB) (data not
shown). In addition, mRNAs of PDGFRA (encoding PDGFRa)
and PDGFRB, as well as their ligand PDGFC, were highly ex-
pressed in basal B subtype of breast cancer cell lines bearing
mesenchymal properties but not in luminal-like cell counterparts
bearing more epithelial features (Figure 4C). PKCa mRNA was
also highly expressed in basal B, and not luminal-like, breast
cancer cells (Figure 4C). This is consistent with the notion that
basal-like tumors contain cells that behave as if they have under-
gone at least a partial EMT (Blick et al., 2008; Sarrio´ et al., 2008).
To determine whether PDGF autocrine signaling might be
activated following an EMT, we surveyed the expression ofcogenic RASG12V Transformation and in CSCs
subcutaneously into NOD-SCIDmice at limiting dilutions of cells, as determined
estern blot indicates levels of RAS expression.
, HMLE-Snail-RAS, HMLE-Slug-RAS, and NAMEC-RAS cells is shown relative
ted with PKCa inhibitors, paclitaxel, or staurosporine are shown. Differential
of equivalent size (0.3 g) NAMEC-RAS and HMLE-RAS tumors is depicted.
LE-RAS tumors were 11 weeks after inoculation of 5 3 105 cells.
S cells (5 3 104) in mice treated with daily intraperitoneal administration of the
he same day as the cells were implanted. Tumors were collected 15 weeks post
ng treatment with the indicated agents is shown. NAMEC-RAS cells (5 3 104)
2 mm in diameter after 4 weeks. Subsequently, mice were treated with daily
ollected 6 weeks later and tumor masses were determined.
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tions. PDGFA, PDGFB, and PDGFD mRNAs were not
expressed in either cell state (data not shown), indicating that
only PDGFC could participate in such autocrine signaling. In
mesenchymal cell populations, PDGFCmRNAwas indeed upre-
gulated (Figure 4D); total and phosphorylated PDGFRa/b pro-
teins were also induced in these cells (Figure 4E). Additionally,
PDGFRA, PDGFRB, and PDGFCmRNAs were upregulated spe-
cifically in the CD44hi/CD24lo stem-cell-enriched subpopulation
(Figure S3A).
We also monitored the activity of PDGFR in the mesenchymal
cell populations. Culturing NAMECs for 24 hr in serum-free,
growth-factor-depleted medium reduced phosphorylation of
PDGFRb modestly relative to NAMECs maintained in complete
medium, whereas application of either a PDGFR-neutralizing
antibody or a PDGFR pharmacologic inhibitor led to a 4.3-
and 6.8-fold reduction, respectively, in p-PDGFRbY751 (Fig-
ure 4F). Conversely, the exposure of the growth-factor-depleted
NAMECs to PDGFC resulted in increased phosphorylation of
PDGFRb (Figure 4F), whereas HMLE cells showed no response
to PDGFC (data not shown). This provided further support for
the specific activation of autocrine PDGF signaling activity
following induction EMT.
Levels of phospholipase C g 1 and 2 (PLCg1 and PLCg2) pro-
teins, which are known to transduce signals from PDGFRa/b to
PKCa (Rhee, 2001), were also elevated in the EMT-TF-trans-
duced and NAMEC cells (Figure 4E). To examine whether
PLCg was activated by PDGFR, NAMECs were treated with
either of two PDGFR inhibitors (PDGFR Inh III and PDGFR Inh
IV). Levels of the two p-PLCg1Y783 and p-PLCg2Y1217 activated
forms were reduced, whereas total PLCg1 and PLCg2 protein
levels remained unaltered (Figure S3B). We next sought to deter-
mine whether PKCa activation was dependent on the observed
activations of PDGFR and PLCg, the latter of which activates
PKCa through its production of diacylglycerol (Saito et al.,
2002). Exposure of NAMECs to a PLCg inhibitor (U73122)
reduced total PKC enzymatic activity (Figure S3C). Likewise,
pharmacologic inhibition of PDGFR in NAMECs reduced PKC
activity (Figure S3C). Together, these results confirmed that
PKCa activity operated downstream of PDGFR and depended
on the actions of PLCg.
Because PDGF autocrine signaling was activated in cells that
had undergone an EMT, we reasoned that this might be impor-Figure 4. EMT Induces a Switch from EGFR to PDGFR Signaling
(A) Western blots of total and p-EGFRY1068 in the indicated EMT-TF-induced HM
same blot.
(B) Dose-response curves (left) of the sensitivities of HMLE-RAS-GFP and NAMEC
between both cell types at LC50 is indicated. Representative immunofluorescent
(C) Quantitative PCR for PDGFRA, PDGFRB, PDGFC, and PKCa mRNA express
(D) Quantitative PCR for PDGFC expression in mesenchymal and epithelial cells
p < 0.05.
(E) Western blots of PDGFRa, PDGFRb, PLCg1, and PLCg2, along with protein
loading controls (GAPDH) were the same as Figure 4A. Samples were loaded an
(F) Shown is the western blot analysis of NAMECs cultured in the absence of grow
treated with either a PDGFC-neutralizing antibody (20 mg/ml) or a PDGFR inhibitor
is represented by the phosphorylation of PDGFRbY751.
(G) Dose-response curves (left) of HMLE-RAS-GFP and NAMEC-RAS-Tom cells
cell types at LC50 is indicated. Representative immunofluorescent images are sh
Data are presented as mean ± SEM. See also Figure S3.
Catant for their survival and that the inhibition of PDGFR could be
useful for the selective killing of CSCs. Comixed NAMEC-Tom-
RAS and HMLE-GFP-RAS cells were treated with each of these
inhibitors. NAMEC-Tom-RAS cells exhibited a 3.2- to 3.8-fold
lower LC50 for the PDGFR inhibitors tested relative to HMLE-
GFP-RAS cells (Figure 4G). It thus appeared that the EMT,
along with the acquisition of CSC-like traits, was accompanied
by a downregulation of EGFR and concomitant upregulation
of PDGFR, highlighting the preferential utilization of different
signaling networks in different cellular states. We noted that a
pharmacologic inhibitor that is completely specific to inhibition
of PDGFRa/b is currently unavailable and the two PDGFRa/b in-
hibitors used here cross-inhibited c-KIT- and VEGFR-associated
tyrosine kinases.
Cell-State-Dependent Utilization of c-FOS or FRA1
during EMT
We sought to elucidate the mechanism(s) through which PKCa
acts to support themesenchymal cell state and to identify down-
stream mediators of PKCa in cells that have undergone an EMT.
We surveyed for PKCa substrates identified by others in various
cellular contexts (Abate et al., 1991; Gruda et al., 1994; Kang
et al., 2012) and focused on those upregulated together with
PKCa expression during an EMT (Figure S4A). Among genes
examined, FOSL1 mRNA (encoding the FRA1 protein) was
the most upregulated target of PKCa in the HMLE-Twist,
HMLE-Snail, and HMLE-Slug cells. This prompted us to further
examine the connection between PKCa and FRA1. Of note, we
could not exclude the possible functional importance of other
genes encoding PKCa substrates that were not transcriptionally
upregulated.
FRA1 is a member of the FOS family of transcription factors
that when phosphorylated downstream of PKCa signaling asso-
ciate with members of the JUN family of transcription factors to
form heterodimeric activator protein-1 (AP-1) complexes to tran-
scriptionally regulate target gene expression (Abate et al., 1991).
To confirm that FRA1 operated downstream of PKCa, NAMECs
were treated with either of two PKCa inhibitors. Levels of
p-FRA1S265 were strongly downregulated, whereas total FRA1
levels remained unchanged, indicating that FRA1 phosphoryla-
tion was indeed dependent on PKCa activity (Figure 5A).
We speculated that c-JUN (encoded by JUN) was a binding
partner of FRA1 because our previous work demonstratedLE and NAMEC cells are shown. Samples were loaded and analyzed on the
-RAS-Tom cells to EGFR inhibitors are shown. The difference in fold sensitivity
images are shown at the right.
ion in breast cancer cell lines is shown. Numbers indicate fold change.
. The asterisk (*) denotes a significant difference from HMLE or HMLE-vector;
phosphorylation, in NAMECs and EMT-TF-induced cells are shown. Sample
d analyzed on the same blot.
th supplements (bovine pituitary extract, EGF, hydrocortisone, and insulin) and
(1 mM) (top), or upon exposure to PDGFC (100 ng/ml) (bottom). PDGFR activity
to PDGFR inhibitors are shown. The difference in fold sensitivity between both
own at the right.
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et al., 2011). Indeed, we found that total and phospho-c-
JUNS63 as well as the Jun N-terminal kinase (JNK), which is
required for the activation of c-JUN, were upregulated in mesen-
chymal cell populations (Figures 5B and S4B). Other JUN family
members, JUNB and JUND, did not exhibit consistent up- or
downregulation following passage through an EMT, indicating
that their expression was not cell-state dependent. Unexpect-
edly, c-FOS (encoded by FOS), which has been extensively
documented as a partner of c-JUN (Eferl and Wagner, 2003),
was downregulated during passage through an EMT (Figures
5B and S4B). Total and phospho-FRA1S265 levels, by contrast,
were increased. Hence, epithelial and mesenchymal cells
appeared capable of assembling AP-1 complexes, but of quite
different composition in that FRA1 seemed to replace c-FOS
as the partner of JUN following passage through an EMT.
We sought to understand the functional significance of the
c-FOS-FRA1 molecular switch during the EMT. Knockdown of
FRA1 with two independent shRNAs preferentially reduced
NAMEC-Tom cell numbers but had a lesser impact on HMLE-
GFP cells (Figures 5C and S4C). In contrast, HMLE-GFP cells
were preferentially depleted upon c-FOS knockdown, whereas
NAMEC-Tom cells were significantly less affected. This high-
lighted the cell-state-specific dependence on either c-FOS or
FRA1 for maintaining cell viability (Figure 5C). We performed
coimmunoprecipitation experiments to validate the formation of
AP-1 complexes and the nature of their constituent subunits. In
NAMECs, immunoprecipitation of FRA1 showed physical asso-
ciation with c-JUN, JUNB, and JUND (Figure 5D). In a reciprocal
manner, pull-down of c-JUN demonstrated its interaction with
FRA1 but not c-FOS (Figure 5D). The converse pattern was
observed in HMLE cells, in which c-FOS strongly associated
with JUNB and JUND but not c-JUN, which was downregulated
in the epithelial state (Figure 5D). Furthermore, chromatin immu-
noprecipitation analyses revealed c-FOS binding to the pro-
moters of genes encoding E-cadherin and Crumb3, two key
epithelial proteins, in HMLE cells. The same promoters, however,
were not bound by FRA1 in NAMECs, which did not express
either protein (Figure 5E). Hence, during execution of the EMT
program, there is a switch from the use of c-FOS to FRA1 as
the preferred component of AP-1 transcription factor complexes.Figure 5. PDGFR Signaling Results in PKCa and ERK1/2 Activation tha
(A) Western blot analysis shows the effects of inhibiting PKCa (using Ro-31-8220
30 min on the phosphorylation status of FRA1 and c-JUN in NAMECs.
(B) Western blots of AP-1 family member subunits in epithelial and mesenchyma
(C) Relative cell number analyses of the effects of FRA1 or c-FOS knockdown on
denotes a significant difference from vector control; p < 0.05. Data are presente
(D) Western blots for proteins immunoprecipitated with FRA1 or c-JUN antibodi
lysates were used as positive controls, whereas pull-down with IgG or without a
(E) Occupancy of c-FOS and FRA1 on the promoters of CDH1 and CRB3 (enco
located within intron 1 (CDH1) or intron 3 (CRB3). Control ChIP was performed w
(F) Western blots of total and phosphorylated B-RAF, c-RAF, and ERK1/2 in TF-
were the same as in Figure 5B. Samples were loaded and analyzed on the same
(G) The amount of GTP-bound Ras was compared between epithelial and mesen
beads followed by blotting with a pan-Ras antibody. As a negative control, lysa
beads. b-actin from whole-cell lysate (prior to IP) was used as a loading control.
(H) Western blots of phosphorylated proteins of B-RAF, c-RAF, MEK1/2, and ER
shown.
(I) Western blots of p-FRA1 levels in NAMEC cells following MEK inhibition for 30
See also Figure S4.
CaControl of FRA1 Activation by ERK Signaling
We sought to uncover additional downstream targets of PKCa
beyond FRA1 that might be crucial for supporting the EMT pro-
gram. c-Raf is another substrate of PKCa that sustains activation
of ERK signaling and helps to promotemesenchymal cell pheno-
types (Kolch et al., 1993). Examination of proteins involved in the
ERK pathway revealed increased expression of both total and
phosphorylated levels of B-RAF, c-RAF, and ERK1/2 in the
mesenchymal cell populations (Figure 5F).
Because ERK signaling is commonly controlled by RAS activ-
ity, we tested whether mesenchymal cells contained higher RAS
expression or activated RAS than did epithelial cells. Interest-
ingly, levels of total RAS and activated GTP-bound RAS were
similar among epithelial and mesenchymal cell types (Figures
5F and 5G). This led us to propose that the enhanced ERK
signaling in the mesenchymal cell state was primarily mediated
by PKCa signaling rather than through the RAS-RAF pathway.
To test this notion, we exposed NAMECs to PKCa inhibitors
and found reduced p-c-RAF, p-MEK1/2, and p-ERK1/2 levels
(Figures 5H and S4D). Inhibitors of PDGFR signaling, likewise,
blunted ERK signaling as indicated by decreased p-c-RAF,
p-MEK1/2, and p-ERK1/2 levels (Figure S4E). Hence, enhanced
activity of ERK signaling during EMT was conferred in part by
signaling through PDGFR and PKCa.
FRA1, which we showed earlier to be downstream of PKCa,
has also been reported to serve as a direct substrate of
p-ERK1/2 (Kakumoto et al., 2006). Thus, we speculated that
the increased p-FRA1 activity in the mesenchymal cells could
be further augmented by elevated ERK signaling. Accordingly,
blockade of ERK1/2 phosphorylation with a MEK inhibitor in
NAMECs decreased p-FRA1 levels but did not affect the levels
of total FRA1 or p-c-JUN (Figure 5I), confirming that ERK1/2
signaling promoted the phosphorylation of FRA1. Together,
these observations indicate that PKCa signaling inmesenchymal
cells leads to activation of FRA1, downstream of both PKCa and
ERK1/2.
Role of FRA1 in Tumor Initiation by Breast Cancer Cells
We sought to understand whether FRA1 might be functionally
important for the subset of human breast cancer cells that exhibit
mesenchymal traits. Accordingly, we depleted FRA1 by RNAi int Induces FRA1
or bisindolylmalmide I) or PDGFRa/b (using PDGFR Inh III or PDGFR Inh IV) for
l cell lines are shown. Samples were loaded and analyzed on the same blot.
the viability of NAMEC-Tom and HMLE-GFP cells are shown. The asterisk (*)
d as mean ± SEM.
es in NAMECs and with c-FOS antibody in HMLE cells are shown. Whole cell
n antibody was performed as negative controls.
ding Crumb3) is shown. A normalization probe for the non-enriched region is
ith an IgG antibody.
induced EMT and NAMEC cells are shown. Sample loading controls (GAPDH)
blot.
chymal cell states by immunoprecipitation with Raf-Ras Binding Domain (RBD)
tes were treated with GDP, which blocked the ability of Ras to bind Raf-RBD
K1/2 in NAMEC cells following treatment with PKCa inhibitors for 30 min are
min are shown.
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and SUM159, both of which do not express HER2, estrogen
receptor (ER), or progesterone receptor (PR). In both cell
lines, FRA1 depletion resulted in a morphologic response
resembling a mesenchymal-epithelial transition (MET), in which
otherwise mesenchymal-like cancer cells formed cobblestone
sheets resembling those assembled by epithelial cells (Fig-
ure 6A). The loss of VIM, FN1, and CDH2 mRNA expression
accompanied by the gain of CDH1 mRNA expression was
observed (Figure 6B). Moreover, in both cell lines depleted of
FRA1, FOS mRNA expression, which we had previously associ-
ated with the epithelial cell phenotype, was strikingly increased
(Figure 6C).
FRA1 knockdown did not significantly affect proliferation of
MDA-MB-231 or SUM159 cells in vitro (Figure S5A). However,
FRA1-depleted cells formed tumors with a reduced frequency
and were a substantially smaller size relative to shRNA controls
when xenografted into female NOD-SCID mice (Figure 6D).
In contrast, depletion of FRA1 in two luminal-like, hormone-
receptor-positive (ER+/PR+) breast cancer cell lines, MCF7-
Ras and T47D, did not affect their proliferation, expression of
EMT-associated markers, tumor formation, or tumor growth
(Figures S5A–S5C). These observations suggested that FRA1
was important for the tumorigenic potential of breast cancer cells
forming basal-like or triple-negative tumors but not those form-
ing luminal tumors.
This led us to speculate that FRA1 expression might be
restricted to the more mesenchymal, CSC-enriched compart-
ments within basal-like human breast tumors. Previous studies
have shown that purified CD44+ or protein C receptor-positive
(PROCR+) cells tend to be enriched for CSCs in primary human
tumors, whereas the CD24+ fraction was depleted of these cells
(Al-Hajj et al., 2003; Shipitsin et al., 2007). Both CD44+- and
PROCR+-purified cells also demonstrated elevated mRNA
expression of VIM (4033), FN1 (483), and TWIST (6.63) (Shipit-
sin et al., 2007). Thus, we further analyzed the expression of
FOSL1 and FOS in these CD44+/PROCR+ or CD24+ cells iso-
lated from human tumors (Shipitsin et al., 2007). Across multiple
specimens, FOSL1was upregulated in the CD44+/PROCR+ frac-
tion, whereas FOS was elevated in the CD24+ fraction (Fig-
ure S5D), providing additional support that FOSL1 expression
is associated with CSC-enriched CD44+ populations bearing
mesenchymal properties.Figure 6. FRA1 Is a Transcriptional Target of Twist and Snail that Is In
(A) Phase contrast images show the morphology of MDA-MB-231 or SUM159 ce
(B) Quantitative PCR for gene expression of mesenchymal markers in FRA1-deple
(C) Quantitative PCR for gene expression of FOS and FOSL1 after FRA1 knockd
(D) Assessment of the tumorgenicity of cancer cells following FRA1 knockdow
implanted into female NOD-SCID mice, tumors were extracted after 4 weeks, a
formation. The asterisk (*) denotes a significant difference from Luc-sh-derived t
(E) Changes in gene expression of EMT markers in Twist-ER and Snail-ER cells a
duration examined.
(F) Occupancy of Twist and Snail on the FOSL1 or FOS promoter is shown. Bind
(FOSL1) or probe 9 (FOS).
(G) Effect of Twist and Snail on FRA1-reporter luciferase activity is shown. Firefly
and the values were compared to control Scr sh or vector overexpression. The ast
(H) This is the quantitative PCR for FOSL1 expression after Twist or Snail knockd
control.
*p < 0.05. Data are presented as mean ± SEM. See also Figure S5.
CaEffects of the Twist and Snail EMT-TFs on FRA1
Expression
The increased expression of FRA1 in the EMT-TF-induced
mesenchymal cells and NAMECs correlated closely with the
abundance of several EMT-TFs, suggesting that the latter might
directly induce FOSL1mRNA expression. To test this notion, we
fused ER to either Twist or Snail (HMLE-Twist-ER and HMLE-
Snail-ER) (Mani et al., 2008) and demonstrated that activation
of Twist or Snail upon tamoxifen exposure led to increased levels
of FOSL1 mRNA in a time-dependent manner (Figure 6E). We
next assessed using chromatin immunoprecipitation (ChIP)
whether Twist and Snail bound at the FOSL1 promoter and could
detect their binding at the transcription start site and within the
first intron of FOSL1 (Figure 6F). These regions contained
E-box motifs (CANNTG), which Twist and Snail are known to
bind. In contrast, the promoter of FOSwas only weakly enriched
for Twist and Snail binding (Figure 6F). Together, these data sug-
gested that FOSL1 was a direct target of Twist and Snail.
To determine whether the ability of FRA1 to drive gene
transcription was dependent on the expression of EMT-TFs,
we utilized a luciferase reporter containing the sequence of a
previously reported FRA1-bound gene promoter (FRA1-wild-
type binding site: FRA1-WT-BS) as well as a mutant FRA1
binding construct (FRA1-mut-BS) (Stinson et al., 2011). In
NAMECs, knockdown of FRA1 abrogated luciferase activity of
the FRA1-WT-BS but not FRA1-mut-BS (Figure 6G, left).
Similarly, knockdown of TWIST or SNAIL diminished FRA1-
dependent expression of the FRA1-WT-BS reporter (Figure 6G,
left). FOSL1 mRNA expression was also reduced upon either
TWIST or SNAIL knockdown (Figure 6H).
In a reverse experiment, we overexpressed FRA1 in the
NAMEC11 cell line, which had undergone a partial EMT. Overex-
pression of FRA1 induced FRA1-WT-BS but not FRA1-mut-BS
luciferase activity (Figure 6G, right). Likewise, Twist and Snail
overexpression in these cells was able to induce transcription
of the FRA1-WT-BS reporter (Figure 6G, right). The wild-type
AP-1 reporter containing tandem repeats of AP-1 response
element was used as a positive control (Figure 6G). Therefore,
these various lines of evidence confirmed that FOSL1 levels
were transcriptionally regulated by two master EMT-TFs and in
a direct manner.
To demonstrate that FRA1 plays a functionally significant
role downstream of EMT-TFs, we activated Twist or Snail indispensible for Tumorigenicity of Basal-like Breast Cancer Cells
lls after FRA1 knockdown for 10 days. Scale bar: 40 mm.
ted cells is shown. The asterisk (*) denotes a significant difference from Luc sh.
own in MDA-MB-231 and SUM159 cells is shown.
n is shown. Subcutaneously, 1 3 106 MDA-MB-231 or SUM159 cells were
nd tumor masses were determined. Numbers indicate the frequency of tumor
umors.
fter the addition of 4-OHT are depicted. Cells were exposed to 4-OHT for the
ing enrichment was normalized to input DNA and plotted relative to probe 12
luciferase was normalized against SV40-Renilla-luciferase transfection control
erisk (*) denotes a significant difference from Scr sh or the vector control; n = 6.
own in NAMECs. The asterisk (*) denotes a significant difference from vector
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absence of two different FRA1 shRNAs and assessed the ability
of these cells to transit into the mesenchymal state. HMLE-
Twist-ER and HMLE-Snail-ER cells that expressed control
shRNA underwent an EMT within 1 week after 4-OH-tamoxifen
exposure (Figures 7A and 7B). However, FRA1-depleted cells
were blocked in their ability to undergo an EMT upon Twist or
Snail activation and retained their epithelial phenotype (Figures
7A and 7B). These observations reinforced our conclusion that
FRA1 acts as an effector of the EMT program that is required
for its execution.
Relevance of FRA1 and PKCa Expression to Clinical
Breast Cancer
The functional significance of FRA1 inmediating cell-state transi-
tion and in maintaining CSCs led us to wonder whether its
expression might also be relevant to clinical breast cancer. We
speculated that FOSL1 expression was restricted to basal B
and triple-negative breast cancer (TNBC) tumors and cell lines
because these bear strong molecular hallmarks of cells that
have activated an EMT program (Shipitsin et al., 2007). These
subtypes are also thought to contain a high representation of
CSCs, thereby favoring relapse,metastasis, andpoor overall sur-
vival. Indeed, FOSL1 mRNA levels, but not those of other AP-1
subunits, were elevated in the basal B subtype of breast cancer
cell lines surveyed, whereas FOSL1 mRNA levels were reduced
in the basal A cell lines and were essentially undetectable in all
luminal subtype cell lines (Neve et al., 2006) (Figure S6A).
From a compendium of clinical data sets, we observed high
FOSL1 expression significantly correlated with poor distant
metastasis-free survival (DMFS), whereas high FOS or FOSB
expression associated with better survival (Figures 7C and
S6B). The expression levels of other AP-1 subunits did not pre-
dict patient outcome (Figure S6B). Additionally, higher PKCa
and FOSL1 mRNA expression was significantly associated
with HER2, ER or PR status, as well as with triple-negative
tumors (Figure 7D). Their expression was also elevated in tumors
bearing BRCA1 mutations and in breast cancer cell lines con-
taining p53 mutations (Figure 7D). Moreover, FOSL1, PDGFRA,
and PDGFRB mRNAs were more highly expressed in the
claudin-low subtype of breast cancer that is thought to express
the most mesenchymal properties (Figure S6C).
To exclude the possibility that FOSL1 mRNA expression was
derived from infiltrating stromal cells, we examined its proteinFigure 7. FRA1 Is a Gatekeeper of the EMT Program and Is Clinically C
(A) Phase contrast images show the morphology of Twist- or Snail-induced EMT
(B) Quantitative PCR for gene expression of EMT-associatedmRNAs in Twist-ER a
shown.
(C) Kaplan-Meier plots of distant metastasis-free survival of breast cancer patient
(bottom) mRNA expression.
(D) Microarray meta-analyses of PKCa and FOSL1mRNA expression in human pr
cell lines bearing p53 mutation (Neve et al., 2006) are shown.
(E) Immunohistochemistry analyses of human breast cancer samples for PKCa a
Representative staining results are shown at the left. The numbers of graded tumo
depicted at the right. The asterisk (*) denotes a significant difference from Grade
(F) Effects of PKCa inhibitor administration (5 mg/kg/day) on the growth of patient-
initiated immediately following implantation and continued for 5 weeks; tumormas
the vehicle.
*p < 0.05. Data are presented as mean ± SEM. See also Figure S6.
Caexpression in breast tumor microarrays derived from patients
whose tumors had been scored for tumor grade. Moderate-to-
strong nuclear FRA1 staining was present predominantly in the
neoplastic cells of Grade 3 tumors that were typically hormone
receptors negative but far less commonly in Grade 1 and Grade
2 tumors or in the normal mammary epithelium (Figure 7E). A
similar trend could be observed with cytoplasmic and mem-
brane-localized PKCa in which moderate-strong staining was
most common in Grade 3 tumors relative to Grade 1 and Grade
2 tumors (Figure 7E). Taken together, these results reinforced the
notion that FRA1, along with PKCa, functions as an important
mediator of the behavior of aggressive basal-like and TNBCs.
In light of the findings that PKCa inhibitors, administered sys-
temically, could inhibit the growth of breast cancer cells bearing
mesenchymal traits and the observation that triple-negative
breast tumors tend to express elevated levels of PKCa, we
tested whether PKCa inhibition could be useful therapeutically
against patient-derived tumor samples. We generated three
patient-derived breast cancer xenografts from triple-negative
tumors (EL12-58, EL12-15, and EL11-26) that had been serially
passaged in NOD-SCID mice following their removal from
patients. We then transplanted these tumor fragments orthotopi-
cally into a fresh set of female NOD-SCID mice and, on the same
day, subjected them to either a PKCa inhibitor or vehicle control
that was administered intraperitoneally daily for 6 weeks. With all
three xenograft lines, tumors that formed in the PKCa-inhibitor-
treated mice were consistently smaller (EL12-15: 65.7%, EL11-
26: 53.3%, and EL12-58: 39.5%) than the control group
(Figure 7F). Thus, inhibition of PKCa appeared to be a potentially
useful strategy for targeting triple-negative breast tumors.
DISCUSSION
We and others have argued previously that effective treatment of
carcinomas depends upon the elimination of minority CSCs in
addition to themajority non-CSC cells in these tumors (Creighton
et al., 2009; Dalerba et al., 2007; Gupta et al., 2009). This led us to
exploit the observation that the EMT program generates cells
that are enriched for stem cell and CSC properties to identify
signaling networks that are preferentially utilized in the cellular
products of an EMT (Figure 8). Our present findings demonstrate
that PKCa is a central regulatory node activated by PDGFR in
CSC-enriched populations. Although PKCa has been implicated
in promoting cancer progression (Griner and Kazanietz, 2007;orrelated with Basal-like or Triple-Negative Breast Tumors
cells after FRA1 depletion. Scale bar: 40 mm.
nd Snail-ER cells following FRA1 knockdown after 7 days of 4-OHT exposure is
s. Patient groups were separated based on FOSL1 (top), FOS (middle), or JUN
imary breast cancer tumor subtypes (Waddell et al., 2010) and in breast cancer
nd FRA1 protein expression in breast tumors with different grades are shown.
rs or normal tissues that were classified based on FRA1 or PKCa expression are
1, Grade 2, or normal specimens.
derived breast tumor xenografts in NOD-SCIDmice are shown. Treatment was
ses were then determined. The asterisk (*) denotes a significant difference from
ncer Cell 24, 347–364, September 9, 2013 ª2013 Elsevier Inc. 361
Figure 8. Scheme Depicting the Differential Utilization of Signaling Networks between Non-CSCs and CSCs upon the Activation of an EMT
Program
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CSCs has been unclear. As a proof-of-principle, we showed
that the pharmacologic inhibition of PKCa can target breast
CSCs selectively and that clinically effective compounds inhibit-
ing PKCa may prove therapeutically useful for treating certain
breast tumors.
The selective dependence of the epithelial versus mesen-
chymal MECs on the function of EGFR and PDGFR is clinically
relevant because EGFR inhibitors are being tested in clinical
trials or in clinical use but often are resulting in limited clinical
responses (Carey et al., 2010). Several studies have pointed
out that such inhibitors enrich for CSCs and can lead to the
outgrowth of more aggressive, chemotherapy-resistant tumor
cell populations (Buck et al., 2007; Thomson et al., 2005). These
studies suggest that the presence of epithelial- and mesen-
chymal-like carcinoma cells within tumors requires the elimina-
tion of both cell types.
The EMT program is initially required for invasion and dissem-
ination of tumor cells, whereas MET has been demonstrated to
promote colonization and metastatic outgrowth (Ocan˜a et al.,
2012; Tsai et al., 2012). An increasing number of observations
suggest that both tumor initiation and metastatic outgrowth
depend on coexisting epithelial and mesenchymal subpopula-
tions; conversely, tumors containing exclusively one or the other
subpopulation appear to be poorly suited in enabling both of
these processes (Brabletz, 2012; Celia`-Terrassa et al., 2012;
Ocan˜a et al., 2012). This implies that although the inhibition of362 Cancer Cell 24, 347–364, September 9, 2013 ª2013 Elsevier Inccancer cells bearing a mesenchymal phenotype could be useful
for preventing tumor initiation and/or dissemination, such a ther-
apeutic strategy needs to be complementedwith treatments that
target already-establishedmetastases and their complements of
non-CSC epithelial cells. Moreover, the EMT should be viewed
as generating a spectrum of phenotypic states depending on
the extent to which this program is completed by epithelial cells,
and partial completion of this program may be essential for the
formation of CSCs and thus the founding of metastases. Future
work will require more detailed measurements of the extent to
which the various intermediate states depend on the epithelial
versus mesenchymal signaling circuits described here.
Our initial efforts to distinguish molecular features between
mammary CSCs and non-CSCs have led to the identification of
kinase inhibitors that may be useful in preclinical models of
human breast cancer. We speculate that the EMT program
mayalso be adopted by other carcinoma cell types to drive tumor
progression and metastasis. If so, the approach used to identify
therapeutic compounds and pathways unique to mammary car-
cinoma CSCs described here may be extended to target CSCs
present in the tumors arising from other epithelial tissues.EXPERIMENTAL PROCEDURES
Kinase Inhibitor Screen
Kinase inhibitors and other biochemicals were obtained from sources listed
in the Supplemental Information. To set up the screen, 75,000 NAMEC-Tom.
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PKCa Signaling Network in Breast Cancer Stem Cellsand 15,000 HMLE-GFP cells were seeded into each well of a 6-well tissue
culture plate. The following day, fresh media containing inhibitors were
added. For control treatment, DMSO was added. Fresh media containing
inhibitors were replaced daily during the 6-day period. For analysis, cells
were trypsinized and flow cytometry was performed to analyze the propor-
tion of surviving cells relative to DMSO-treated control for NAMEC-Tom or
HMLE-GFP cells. To test the effects of these inhibitors on CSCs and non-
CSCs, NAMEC-RAS-Tom and HMLE-RAS-GFP were used in similar comixed
experiments.
Cell Lines and Cell Culture
HMLE cells and NAMECswere maintained in MEGM (Lonza). Other commonly
used breast cancer cell lines are listed in Supplemental Information. HMLE
were generated from HMECs immortalized using retroviral vectors to express
the catalytic subunit of the human telomerase enzyme, hTERT, and the SV-40
Large T antigen. NAMECs were isolated based on the observation that mesen-
chymal cells were less adherent than epithelial cells to tissue culture surfaces.
HMLE cells were grown to 50% confluency, followed by differential trypsiniza-
tion for 1 min with 0.05% trypsin. Detached cells were collected and replated
at approximately 200 cells per well of a 24-well plate. Upon expansion, wells
were screened for populations with a mesenchymal phenotype that could be
stably propagated.
Gene Expression Microarray and Analyses
Total RNA was extracted and expression profiling of coding genes was carried
out using Illumina HumanRef-8 v2 BeadArrays. Gene expression data from
Illumina array are normalized by quantile normalization. Differential genes
are called using LIMMA with p < 0.05 and fold change > 1.2.
Patient-Derived Breast Cancer Xenograft Establishment and
Therapy
Primary human breast cancer samples were obtained from the Dana-
Farber Cancer Institute with patients’ consent and institutional review
board approval. These samples were subsequently deidentified to protect
patient confidentiality. Patient-derived breast tumor fragments (approxi-
mately 3 3 1 3 1 mm) were inserted bilaterally into the inguinal mammary
fat pads of 6- to 8-week-old NOD-SCID-IL2Rgc/ female mice for initial
establishment of tumors within 2 hr of surgery and subsequently expanded
in NOD-SCID mice once established. Established TNBC tumors (EL12-15,
EL12-58, and EL11-26) were implanted into cohorts of 6- to 8-week-old
female NOD-SCID mice. Treatment was initiated at the time of tumor
implantation and the mice were randomized into two groups: vehicle (10%
DMSO in saline) and treatment (Ro-31-8220, 5 mg/kg/day intraperitoneally).
Tumors were collected and weighed after 6, 8, or 11 weeks. All research
involving animals complied with protocols approved by the MIT Committee
on Animal Care.
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Microarray data are deposited in the NCBI GEO repository with accession
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